Children between the ages of 3 and 8 are eligible to enroll in this Phase III clinical trial of CM-AT.
You might not necessarily know if your child meets eligibility requirements, so the study investigators will conduct study-related assessments to help determine if your child qualifies. There are no needles and no pills!
Autism diagnostic assessments are included. All study evaluations and treatments are provided at no cost to participants.
Many children with Autism exhibit impaired protein digestion which may or may not manifest in self-restricted diets. The inability to digest protein affects the availability of essential amino acids in the body. CM-AT is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids.
Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine.
Investigators want to see if the study medication, CM-AT, may help improve symptoms of Autism. Researchers will evaluate children using psychological, medical, behavioral and developmental measures.
Blüm, a study of the biologic CM-AT for the treatment of Autism, is enrolling children between the ages of 3 and 8 in this Phase III clinical trial at sites across the United States. Please visit clinicaltrials.gov or contact a site near you for more information. If you don't see a trial site near you, please contact firstname.lastname@example.org for more information.